Cantor Fitzgerald reiterates Overweight on Replimune Group stock By Investing.com
Cantor Fitzgerald has reiterated an Overweight rating on Replimune Group (NASDAQ:REPL) following the launch of its drug Tudriqev for melanoma treatment. Despite a significant stock surge over the past year, InvestingPro analysis suggests the shares may be overvalued, noting the company's rapid cash burn as it invests in the Tudriqev launch. The article highlights analyst optimism with price targets up to $24 and recent upgrades from other firms like Wedbush and Leerink, driven by positive FDA approvals and advisory committee votes for Tudriqev.
Securities Lawsuit Alert: Replimune Group, Inc. (REPL) - Contact Levi & Korsinsky Before October 5, 2026
Levi & Korsinsky, LLP has announced a securities class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false statements and concealed issues regarding its Biologics License Application (BLA) for RP1-104, including unaddressed FDA concerns and the use of early, limited data. Shareholders affected by these alleged securities frauds are encouraged to contact Levi & Korsinsky before October 5, 2026, to explore potential recovery options.
Class Action Filed Against Replimune Group, Inc. (REPL) Over Securities Violations - Contact Levi & Korsinsky Today
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who suffered losses due to alleged securities fraud. The lawsuit claims that Replimune made false statements and concealed information regarding deficiencies in their BLA study design and data, which were likely to cause the FDA to reject the BLA. Investors who purchased Replimune securities between October 20, 2025, and April 10, 2026, are encouraged to contact Levi & Korsinsky to explore their rights.
Insiders At Replimune Group Sold US$1.6m In Stock, Alluding To Potential Weakness
Insiders at Replimune Group have sold US$1.6 million worth of stock over the last year, with no purchases recorded. This sell-off, particularly by CEO Philip Astley-Sparke, indicates potential concerns about the company's future prospects despite a 6.9% share price increase in the past week. Investors often view insider selling as a signal of possible future underperformance.
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
Replimune announced that TUDRIQEV™ (vusolimogene oderparepvec-wtpg), an oncolytic immunotherapy, is now commercially available in the U.S. for adult patients with unresectable advanced cutaneous melanoma who have experienced disease progression with a PD-1-blocking antibody-based regimen. The approval was accelerated based on objective response rate and duration of response from the IGNYTE trial, and continued approval is contingent on confirmatory trials. Replimune has also launched ReplimuneConnect Plus, a comprehensive patient support program to assist with access, reimbursement, and financial assistance for eligible patients.
Lost Money on Replimune Group, Inc. (REPL)? Join Class Action Before October 5, 2026 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Replimune Group, Inc. (NASDAQ:REPL) on behalf of investors who suffered losses. The lawsuit alleges that Replimune made false statements and concealed issues regarding its BLA submission for RP1-104, including unaddressed FDA concerns and insufficient patient data. Investors who purchased REPL securities between October 20, 2025, and April 10, 2026, are encouraged to contact Levi & Korsinsky to learn about their rights before the October 5, 2026 deadline.
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm
Levi & Korsinsky, LLP has filed a securities class action against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made misleading statements regarding its RP1 biologics license resubmission, which led to a significant stock price decline when the FDA rejected the BLA. Investors have until October 5, 2026, to apply for lead plaintiff.
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
Replimune has announced that TUDRIQEV™ (vusolimogene oderparepvec-wtpg) is now commercially available in the U.S. for adult patients with unresectable advanced cutaneous melanoma that has progressed after PD-1-blocking antibody treatment. This accelerated approval is based on objective response rate and duration of response data from the IGNYTE trial. The company has also launched ReplimuneConnect Plus, a support program to help eligible patients access the treatment.
Replimune Group Inc (REPL-Q) Stock Price and News
This article provides current stock price information and recent news for Replimune Group Inc (REPL-Q). It highlights various analyst ratings, equity offerings, FDA panel discussions, and financial results, along with legal investigations concerning alleged misleading information. The company is a clinical-stage biotechnology firm focused on developing oncolytic immunotherapy for cancer.
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for alleged violations of federal securities laws. The lawsuit claims Replimune made false or misleading statements regarding its business, operations, and prospects, particularly concerning deficiencies in its BLA submission to the FDA. Investors who purchased Replimune securities between October 20, 2025, and April 10, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of October 5, 2026.
Replimune CEO and CFO sued for allegedly misleading investors on FDA study concerns, causing stock to plunge.
Replimune Group's CEO Sushil Patel and CFO Emily Hill are facing a securities class action lawsuit for allegedly misleading investors regarding unresolved FDA study-design issues related to their RP1 biologics license resubmission. The lawsuit claims they falsely presented the resubmission as complete, leading to a significant drop in Replimune's stock price from $10.73 to $1.70. Investors who purchased shares during this period may be eligible to recover losses, with the lead plaintiff application deadline set for October 5, 2026.
SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL
SueWallSt has issued a reminder to investors of Replimune Group, Inc. (REPL) regarding a pending class action lawsuit. The reminder highlights that the deadline for a lead plaintiff to come forward in this lawsuit is October 5, 2026. This news item provides only a headline, indicating the importance of the upcoming deadline for affected investors.
SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL
SueWallSt is alerting investors of Replimune Group, Inc. (NASDAQ: REPL) about a pending securities class action lawsuit, with a lead plaintiff deadline of October 5, 2026. The lawsuit alleges that CEO Sushil Patel and CFO Emily Hill failed to disclose unresolved FDA study-design concerns regarding Replimune's RP1 biologics license resubmission, leading to significant stock price decline. Investors who purchased REPL securities between October 20, 2025, and April 10, 2026, may be eligible to recover losses and are encouraged to contact SueWallSt.
REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has issued a shareholder alert for investors of Replimune Group, Inc. (NASDAQ: REPL) who suffered losses between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune based its RP1 regulatory strategy on single-arm trial designs and response criteria that the FDA had previously questioned and found inconsistent with RECIST v1.1 standards. Investors have until October 5, 2026, to seek appointment as lead plaintiff in the class action, which was filed in the United States District Court for the District of Massachusetts.
Preferred dividends of Replimune Group, Inc. – HAN:7R8
This article focuses on the preferred dividends of Replimune Group, Inc. (HAN:7R8). It provides a general overview of the company's financial information, specifically highlighting dividend data, without offering specific dividend values or changes. The content is primarily a placeholder within a financial data platform.
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky Before October 5, 2026 to Join Class Action
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who suffered losses between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false statements and concealed issues with its BLA submission to the FDA, including unaddressed study design concerns and reliance on limited early analysis data. Investors are encouraged to contact Levi & Korsinsky before October 5, 2026, to explore their rights and potential recovery.
REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff?
Replimune (REPL) stock fell 11% after-hours despite receiving accelerated FDA approval for its melanoma therapy, TUDRIQEV, in combination with nivolumab. The approval is contingent on a confirmatory late-stage trial, following two prior rejections. The selloff is driven by retail investor concerns about the drug not achieving full approval and doubts about the company's profitability and execution.
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel &
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Replimune Group Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made misleading statements regarding deficiencies in its Biologics License Application that were likely to lead to FDA rejection. Investors have until October 5, 2026, to apply for the lead plaintiff role.
Quick ratio of Replimune Group, Inc. – HAN:7R8
This page from TradingView provides financial information for Replimune Group, Inc. (HAN:7R8), specifically focusing on its quick ratio. The article itself is very brief and mostly consists of navigational elements and copyright information, indicating that detailed financial data would be presented elsewhere on the platform.
Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1
Robbins LLP is investigating Replimune Group, Inc. following a class action lawsuit alleging the company misled investors about the efficacy and viability of its lead product candidate, RP1. The lawsuit claims Replimune failed to disclose issues with its Biologics License Application (BLA) for RP1, which ultimately led to the FDA rejecting the application and a significant drop in the company's share price. Investors who purchased REPL securities during the Class Period (October 20, 2025, to April 10, 2026) may have legal rights and are encouraged to contact Robbins LLP.
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false and misleading statements regarding its business, operations, and prospects, specifically concerning deficiencies in its BLA submission to the FDA. Investors who suffered losses are encouraged to join the case, with a lead plaintiff deadline of October 5, 2026.
REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune failed to disclose that its RP1 trial designs did not address FDA concerns, leading to a significant stock price decline of 84.16% after the FDA rejected the RP1 biologics license application. Institutional investors are encouraged to evaluate lead plaintiff options and contact the firm for a loss assessment.
October 5, 2026 Deadline Approaching: Join Class Action Against Replimune Group, Inc. (REPL) - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Replimune Group, Inc. (REPL) on behalf of investors who suffered losses due to alleged securities fraud between October 20, 2025, and April 10, 2026. The lawsuit claims Replimune made false statements regarding its BLA submission for RP1, failing to address FDA concerns and submitting incomplete data. Investors have until October 5, 2026, to join the class action.
Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before October 5, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Replimune Group, Inc. (NASDAQ:REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false statements and concealed critical information regarding the FDA's concerns about their BLA submission and study designs, leading to significant investor losses. Investors who suffered losses are urged to contact Levi & Korsinsky to learn about their rights to potential recovery.
Lost Money on Replimune Group, Inc. (REPL)? Urged to Join Class Action Before October 5, 2026 – Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who suffered losses due to alleged securities fraud between October 20, 2025, and April 10, 2026. The lawsuit claims Replimune made false statements and concealed issues with its BLA submission to the FDA, which were likely to cause rejection. Investors are urged to contact Levi & Korsinsky before October 5, 2026, to explore potential recovery.
Understanding the Setup: (REPL) and Scalable Risk
Replimune Group Inc. (NASDAQ: REPL) is showing weak near and mid-term sentiment but has a strong long-term positive outlook. AI models have generated three trading strategies (Position, Momentum Breakout, Risk Hedging) with an exceptional 136.0:1 risk-reward setup targeting a 36.8% gain versus 0.3% risk. The long-term signal is strong with a target of $15.17 and support at $11.09.
Replimune faces securities lawsuit over alleged misleading FDA trial data claims on RP1 drug resubmission.
Replimune Group is facing a securities class action lawsuit for allegedly misleading investors about its RP1 drug resubmission to the FDA. The lawsuit claims that Replimune stated all FDA concerns were addressed, despite the FDA's Complete Response Letter indicating inadequate trial data and unresolved study design issues. Following the FDA rejection and subsequent stock price drop, investors are seeking to recover losses, with a lead plaintiff deadline set for October 5, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false and misleading statements and failed to disclose critical study design concerns and data deficiencies that led to the FDA's likely rejection of its Biologics License Application (BLA). Investors are encouraged to join the case by October 5, 2026, to potentially be appointed as lead plaintiff, with the firm operating on a contingency fee basis.
REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026
SueWallSt is reminding investors of Replimune Group, Inc. (REPL) that the deadline to apply for lead plaintiff in a securities class action lawsuit is October 5, 2026. The lawsuit alleges that Replimune Group, Inc. misrepresented the completeness of its RP1 resubmission to the FDA, which ultimately resulted in a significant drop in stock price after the FDA issued a Complete Response Letter. Investors who purchased REPL securities between October 20, 2025, and April 10, 2026, may be eligible to recover losses.
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased shares between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made misleading statements regarding its RP1 biologics license resubmission, specifically concerning unaddressed FDA study design concerns and insufficient data. Following the FDA's rejection of the RP1 BLA, Replimune's stock price experienced a significant decline.
Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit stems from the FDA's rejection of Replimune's Biologics License Application for RP1, citing deficiencies in study design and insufficient evidence for effectiveness, which led to a significant drop in Replimune's stock price. Investors have until October 5, 2026, to file a lead plaintiff motion.
REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug
Replimune Group Inc. (REPL) shares dropped significantly after the FDA released documents questioning the approval of its experimental cancer drug, RP1. This marks the company's third attempt to gain accelerated approval for RP1, and Wall Street now views its clearance as increasingly uncertain. Both Wedbush and BMO Capital expressed concerns, though Wedbush still anticipates a favorable panel vote on efficacy despite the FDA's critical stance.
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made misleading statements regarding its BLA submission for RP1-104 by failing to address FDA concerns and submitting insufficient data. Investors who suffered losses are encouraged to contact the firm by October 5, 2026, to request lead plaintiff status.
REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has alerted investors of Replimune Group, Inc. (NASDAQ: REPL) about a pending securities class action. The lawsuit alleges that Replimune supported its RP1 biologics license resubmission with insufficient data, leading to a significant stock decline. Investors who purchased shares between October 20, 2025, and April 10, 2026, and suffered losses, have until October 5, 2026, to apply for lead plaintiff status.
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) and some of its officers. The lawsuit seeks damages for alleged violations of federal securities laws on behalf of investors who purchased Replimune securities between October 20, 2025, and April 10, 2026. The complaint alleges that Replimune made false and misleading statements and failed to disclose critical information regarding its study designs and BLA submission to the FDA.
Replimune to Present at the Cantor Global Healthcare Conference 2026
Replimune, Inc. announced that its management team will present in a fireside chat at the Cantor Global Healthcare Conference on September 10, 2026, at 9:10 AM ET. A webcast of the presentation will be available on Replimune's website, with a replay accessible for 30 days. Replimune is a commercial-stage biotechnology company focused on developing oncolytic immunotherapies for cancer treatment.
Avoiding Lag: Real-Time Signals in (REPL) Movement
This article provides real-time signals for Replimune Group Inc. (NASDAQ: REPL) from Stock Traders Daily's AI models. It identifies a near-term neutral sentiment amidst mid and long-term strength, offering specific trading strategies including position trading, momentum breakout, and risk hedging with entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
Replimune Group (REPL) stock surged 85.7% after announcing alignment with the FDA for the resubmission of its biologics license application (BLA) for RP1 in combination with Bristol Myers’ Opdivo for advanced melanoma. The FDA plans to prioritize the review of the BLA, which is expected to be resubmitted soon, acknowledging the urgent unmet medical need. This development follows previous complete response letters from the FDA regarding the BLA, which Replimune had contested.
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Levi & Korsinsky, LLP has issued a shareholder alert regarding a securities class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL). The lawsuit alleges that Replimune misled investors between October 20, 2025, and April 10, 2026, by stating its RP1 FDA resubmission was on track despite unresolved study-design concerns. Investors who purchased shares during this period and suffered losses may be eligible to recover damages and have until October 5, 2026, to seek lead plaintiff status.
Replimune Group stock hits 52-week high at 16.2 USD
Replimune Group Inc. (REPL) stock reached a new 52-week high of $16.20, reflecting a 165.99% increase over the past year. This surge follows the FDA's accelerated approval of its cancer treatment, TUDRIQEV, leading to multiple analyst upgrades and optimistic price targets. Despite being considered overvalued by InvestingPro, strong investor confidence and positive market sentiment continue to drive its growth.
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Replimune Group, Inc. (NASDAQ:REPL) for alleged federal securities law violations. The lawsuit claims Replimune made false or misleading statements regarding its business, operations, and prospects, specifically concerning deficiencies in its BLA submission to the FDA. Investors who purchased Replimune securities between October 20, 2025, and April 10, 2026, have until October 5, 2026, to request to be appointed as lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) alleging violations of federal securities laws. The lawsuit claims Replimune made false and misleading statements regarding deficiencies in its BLA submission to the FDA, which were likely to cause rejection. Investors who purchased Replimune securities between October 20, 2025, and April 10, 2026, are encouraged to join the case, with a lead plaintiff deadline of October 5, 2026.
Replimune Group stock hits 52-week high at 15.72 USD By Investing.com
Replimune Group Inc. (REPL) stock reached a 52-week high of $15.72, reflecting a 174.3% increase over the past year. Despite an InvestingPro analysis suggesting it may be overvalued, the company has seen positive analyst upgrades and FDA approval for its cancer treatment TUDRIQEV. These developments highlight the company's growth and strategic progress in the biotechnology sector.
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) and its officers. The lawsuit alleges that Replimune made false or misleading statements regarding deficiencies in its BLA submission to the FDA. Investors who purchased Replimune securities between October 20, 2025, and April 10, 2026, are encouraged to join the lawsuit, with a deadline of October 5, 2026, to request lead plaintiff status.
Investors can lead lawsuit over Replimune's alleged securities fraud and misleading FDA data disclosures
Glancy Prongay Wolke & Rotter LLP has initiated a class action lawsuit against Replimune Group, Inc., accusing the company of securities fraud. The lawsuit alleges that Replimune made false statements and concealed crucial information regarding FDA study design issues and early trial data, misleading investors about its prospects and causing financial losses. Investors impacted by these alleged actions have until October 5, 2026, to seek lead plaintiff status in the lawsuit.
Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has announced that investors who suffered losses in Replimune Group, Inc. (REPL) have an opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that Replimune Group, Inc. made materially false or misleading statements and failed to disclose critical information regarding its Biologics License Application (BLA) for its drug RP1, specifically concerning unaddressed FDA study design concerns and the submission of insufficient data. Investors have until October 5, 2026, to move the Court to serve as lead plaintiff.
REPL Stockholders Have Rights – If You Lost Money Investing
Robbins LLP has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune misled investors regarding the efficacy of its lead product candidate RP1, failing to address FDA concerns in its Biologics License Application (BLA). This led to a significant drop in the company's stock price after the FDA rejected the BLA.
REPL Stockholders Have Rights – If You Lost Money Investing
Robbins LLP, a shareholder rights law firm, has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune misled investors regarding the efficacy of its lead product candidate, RP1, which led to a significant stock drop after the FDA rejected its Biologics License Application. Investors who suffered losses are encouraged to contact Robbins LLP by October 5, 2026, to learn about their legal rights and potentially become lead plaintiff.
Replimune Group stock hits 52-week high at 15.72 USD By Investing.com
Replimune Group's stock reached a 52-week high of $15.72, showing a significant 174.3% increase over the past year, driven by strong investor confidence and advancements in biotechnology. While InvestingPro suggests it might be overvalued, recent positive analyst upgrades and the FDA approval of its cancer treatment TUDRIQEV (RP-1) have contributed to a positive outlook for the company's future prospects. The company is also expected to release its earnings report soon.
Replimune Group stock hits 52-week high at 15.72 USD By Investing.com
Replimune Group (REPL) stock reached a 52-week high of $15.72, showing a 174.3% increase over the past year, reflecting strong investor confidence despite being considered potentially overvalued by InvestingPro. This surge follows positive analyst upgrades and the FDA approval of their cancer treatment TUDRIQEV, highlighting the company's growth in the biotechnology sector.
